Literature DB >> 1735701

Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme.

W F Ward1, A Molteni, C H Ts'ao, Y T Kim, J M Hinz.   

Abstract

The present study determined whether inhibitors of angiotensin converting enzyme (ACE) can ameliorate radiation-induced pulmonary endothelial dysfunction and pulmonary fibrosis in rats sacrificed 2 months after a range of single doses of 60Co gamma rays to the right hemithorax. Four indices of pulmonary endothelial function were monitored: right lung ACE and plasminogen activator (PLA) activity, and prostacyclin (PGI2) and thromboxane (TXA2) production. Hydroxyproline (HP) content served as an index of pulmonary fibrosis. Rats consumed either control powdered chow or feed containing one of five modifying agents continuously after irradiation. The modifiers included three ACE inhibitors: Captopril, CL242817, and CGS13945, respectively, a thiol, a thioacetate, and a nonthiol compound. All of the ACE inhibitors are analogues of proline. Two additional modifiers were tested: penicillamine, a thiol with no ACE inhibitory activity; and pentoxifylline, a vasodilator that is neither a thiol nor an ACE inhibitor. Radiation produced a dose-dependent decrease in lung ACE and PLA activity, and an increase in PGI2 and TXA2 production and in HP content. All ACE inhibitors attenuated the radiation-induced suppression in lung ACE and PLA activity. All thiol or thioacetate compounds ameliorated the radiation-induced increase in PGI2, TXA2, and HP. The two agents that were both thiols and ACE inhibitors (Captopril and CL242817) spared all of the radiation reactions, while the compound that was neither a thiol nor an ACE inhibitor (pentoxifylline) spared none of the reactions. These data suggest a novel application for ACE inhibitors in general, and for Captopril in particular, as modifiers of radiation pneumotoxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735701     DOI: 10.1016/0360-3016(92)90890-t

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

3.  A bioinformatics approach for biomarker identification in radiation-induced lung inflammation from limited proteomics data.

Authors:  Jung Hun Oh; Jeffrey M Craft; Reid Townsend; Joseph O Deasy; Jeffrey D Bradley; Issam El Naqa
Journal:  J Proteome Res       Date:  2011-02-16       Impact factor: 4.466

4.  Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study.

Authors:  Whitney D Gannon; Michaela R Anderson; Anna J Podolanczuk; Steven M Kawut; Erin D Michos; Vincent Cottin; Michael Kreuter; Ganesh Raghu; R Graham Barr; David J Lederer
Journal:  Ann Am Thorac Soc       Date:  2019-11

Review 5.  New strategies for treatment of pulmonary fibrosis.

Authors:  S H Phan
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

6.  Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time.

Authors:  Samuel Ryu; Andrew Kolozsvary; Kenneth A Jenrow; Stephen L Brown; Jae Ho Kim
Journal:  J Neurooncol       Date:  2006-09-27       Impact factor: 4.130

Review 7.  Radiation damage to the lung: mitigation by angiotensin-converting enzyme (ACE) inhibitors.

Authors:  Meetha Medhora; Feng Gao; Elizabeth R Jacobs; John E Moulder
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

Review 8.  Myocardial repair/remodelling following infarction: roles of local factors.

Authors:  Yao Sun
Journal:  Cardiovasc Res       Date:  2008-12-02       Impact factor: 10.787

9.  Early and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage.

Authors:  Benjamin Gauter-Fleckenstein; Katharina Fleckenstein; Kouros Owzar; Chen Jiang; Júlio S Rebouças; Ines Batinic-Haberle; Zeljko Vujaskovic
Journal:  Free Radic Biol Med       Date:  2010-01-20       Impact factor: 7.376

Review 10.  Advances in mechanisms of repair and remodelling in acute lung injury.

Authors:  Claudia C Dos Santos
Journal:  Intensive Care Med       Date:  2008-02-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.